Tango Therapeutics launches $100M at-the-market stock offering
- Tango Therapeutics (TNGX) entered a sales agreement with Leerink Partners to sell up to $100M of common stock through an at-the-market offering.
- Leerink Partners will use commercially reasonable efforts to sell shares and will receive up to a 3% commission on gross proceeds.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.